sp
ki
lowing
trans
email
distinguished
taken
recruitment
london
withdrawal
pyrimeth
lets
participant
medicine
shown
af
excluded
e20
previous
recurrent
contribute
interview
350
access
discretion
101
contributions
tympanic
recurred
malar
placed
address
presence
urban
mild
thank
prema
project
ended
diotoxic
2002
context
option
definite
death
ications
supported
there
gd
regi
giving
headache
larial
meier
letitia
ran
stepwise
tolerabil
identify
quinine
vastly
sulfamethoxazole
treated
falciparum
arunkamomkiri
outcome
444
occur
yau
info
medsfgh
cmaiteki
peter
dyscrasias
directly
dis
hear
joseph
inter
few
toler
authors
zwang
kramer
001
researc
wash
ltd
african
keppel
immediately
discus
zongo
acceptance
compounds
domised
return
parum
gather
artemether
rwagacondo
intervals
serious
ity
keep
fine
jl
episode
outpatient
yours
fracture
mrk
interest
curtis
final
pharmaceuticals
ao
dur
notransferase
therapies
men
resulting
hallett
treatments
clinical
properly
screened
subsequent
recipient
htm
danger
diagnosed
ami
ipant
drugs
arms
treating
known
reproductive
unclear
temperatureγ
323
evening
differences
fritz
falade
additional
signifi
visits
sented
bility
005
associa
person
biomedical
uncommon
reporting
primarily
relying
biologics
ano
spontaneously
neutropaenic
estimating
660
table
inferiority
perception
slum
line
inpatient
359
apies
treatmentδ
108
bakyaita
fantrine
naome
330
142
physicians
registration
references
findings
house
plus
fanello
met
auditory
need
white
could
does
missed
per
outside
performed
collecting
passive
sanofi
research
young
center
considering
trials
htoo
sion
bring
physical
9469
indicated
both
statistics
disseminating
rede
regina
ments
licensee
conflicts
rt
jagannathan2
period
although
geertruyden
important
basaliza
trop
rev
prior
comparison
convulsions
all
microsoft
thy
located
2006
administered
pairwise
exchangeable
significantly
cor
total
776
coartem
development
ences
diff
support
object
submit
control
including
global
adopted
010
car
unless
arinaitwe
surgical
february
complete
third
content
sensitization
premature
malaria
artemisinin
submission
rossier
bm
hours
440
karema
disease
agree
ence
planning
below
021
sebuguzi1
during
dosed
cardiotoxicity
tclark
probable
sk
multiple
approach
ministry
efficacy
hot
parasitae
grade
rosenthal
elsewhere
absence
methods
guiguemde
saf
duration
smear
grateful
prophylaxis
resolution
moses
ticipants
exposures
district
closely
sions
writing
age
recommended
higher
birabwa
tests
van
distributed
results
sus
004
antimalarial
saes
likelihood
whitty
998
1186
attribution
details
appear
open
kasule
alanine
arsumax
significant
coryza
extended
area
participated
neutro
njama
pediatrics
u01a1052142
morrow
encounter
aminotransferase
piperaquine
designed
post
annette
funding
comes
norah
induced
bbosa
mens
doris
pooled
measures
1052
four
they
novartis
reachbridget
344
adverse
diagnosis
popula
117
tk
levi
davis
julia
experience
individual
atalisuna
garner
entire
who
aa
tireless
clinic
according
emmanuel
previously
experiencing
simple
cycle
desired
419
ture
suggest
staff
database
mak
participation
365
phillips
je
0oc
haematology
failure
factors
commonly
plos
pick
consisting
main
near
referral
calculation
basic
antima
pre
dapsone
491
alternative
pi
studies
effects
receiving
berkeley
excellent
1480
date
many
median
causal
intensive
antimalarials
life
subject
prac
roche
symptoms
system
steketee
author
mugenyi
utility
palacios
act
neutropenia
greenwood
initiated
every
college
enrolled
provide
382
002
lacking
bly
129
national
appears
identifier
addition
charitable
168
sulfadoxine
fol
risk
san
care
addressed
remaining
mebrahtu
beginning
sig
permits
highly
743
similarly
drawal
focusing
patient
bukirwa
gimnig
concerning
351
presented
study
yahoo
arm
description
looareesu
1498
andriano
cd005564
clark
outcomes
gmail
errors
california
lefevre
case
deaths
alone
mittelholzer
ated
little
combination
integrated
talisuna
assignments
about
9404
sites
120
defined
ened
mkandala
amine
ringwald
392
begun
overmeir
hutagalung
md
combina
rosenthal2
jp
pascal
regimen
threaten
bojang
fied
unwilling
tab
fansidar
original
017
soc
791
cough
episodes
administer
vincent
mal
normal
technical
008
arte
bindschedler
mulago
doi
east
published
tive
monitoring
obtaining
improved
wan
possible
later
representing
station
sampling
members
length
traumatic
cost
resolved
active
trimoxazole
redmond
impact
premji
britain
mon
severity
raising
toring
under
mia
hygiene
nsobya
498
1487
withdrawn
coulter
move
gathmann
namuyiga
our
its
currently
osaliya
med
conceived
lankoande
catherine
measurements
signs
collection
amodi
frame
pyrimethamine
991
group
ch
incapacity
accredited
home
deployed
kamya1
movement
provided
geoff
2219
toxicity
superior
accepted
relatively
293
967
2department
mangen
medical
talemwa
vomiting
tertiary
end
treatment
nosed
gathered
mether
long
commons
placebo
hunt
classified
hyg
than
fever
just
nate
initial
effective
department
monitored
ent
mariam
pregnancy
consolidated
vugt
ezzet
central
history
diag
ahmed
dihydroartemisinin
plicated
meules
tion
technology
appointment
follow
effort
several
continued
richard
suspected
longitudinal
chil
2000
malpractice
cells
havlir
consent
ln
baseline
practice
singhasivanon
might
bio
following
ich
parent
definitely
campbell
data
9560
faye
camoquin
treat
cochrane
par
corresponding
council
after
pjr
discussion
355
amodiaquine
alt
back
disa
as
kenneth
2005
drakeley
moderate
jb
dor
collaboration
vi
interested
gaye
second
sulphadoxine
versus
difference
belgium
repeat
mkamya
counts
lugemwa
plans
reported
wc1e
rence
hepatitis
randomised
assessment
child
work
kamya
recruited
demographic
e6
portions
sodes
medications
new
evaluation
conducted
org
tdc
worsening
emerged
pro
reviewed
guidance
three
limitations
cutaneous
harmonisation
respectively
needed
develop
exam
april
feeling
harmonization
kilama
settings
362
was
experienced
draogo
two
conclusion
2496
notewor
deemed
lebras
count
finger
each
298
cited
africa
senegal
regions
your
role
isinin
variable
bone
assess
106
964
pant
experi
attention
accordingly
occurrence
meya
differ
profile
resulted
audiometric
ponent
1990
tropical
participants
halofantrine
weight
impacted
criteria
countries
rais
generally
suggests
howard
749
268
345
596
strengthened
omari
censoring
sode
limit
available
consistent
imen
drawn
antwerp
approved
eight
however
bronchopneumonia
testing
double
patients
1105
compared
senfuma
one
denise
ashley
combinations
did
relationship
sidered
929
nausea
estimated
any
396
allowed
site
blinded
more
karbwang
erere
usa
groups
δrisk
laboratory
mpindi
standardized
kaplan
considered
threatening
detailed
most
greenhouse
sequentially
had
approval
information
venture
356
ical
marx
neutropaenia
chronic
finan
bination
reasons
measurement
interpretations
gdorsey
relevant
objective
ga
lim
lj
medicines
will
cobas
much
infected
neither
skin
211
parasitaemia
iii
subjec
assessing
lifetime
389
seen
incomplete
captured
cause
sample
drug
upon
only
infection
neurotoxicity
associations
correlation
ill
007
recorded
sebuguzi
blind
avoid
160
jama
dieng
mussano
equations
nosten
119
biomed
publishing_adv
anorexia
sustained
malarial
carol
seven
003
good
fulfilled
intention
journal
dependent
lavoy
rash
west
concern
systematic
then
rd
013
roll
tal
sturchler
probably
sidering
john
nakafeero
381
delayed
associated
modify
asaba
blood
uganda
increasing
duke
wm
trape
come
preparation
ci
least
formula
less
zerland
1993
due
400
newman
collected
analysis
ambrose
dihy
pyretic
carrara
increased
tinto
bako
frequent
ouedraogo
requir
six
fixed
approached
received
tx
immaculate
last
tionship
food
kampala
often
1201
unrelated
sarah
yau3
reflect
creativecommons
kemble
next
029
restricted
daily
similar
oral
value
cooperation
finding
francisco
sioufi
2210
evaluated
biomedcentral
changes
hold
areas
aot
described
faso
affiliations
relationships
felt
same
restricting
science
free
mr
anti
kampiire
industry
parke
license
ampeire
robust
epidemiology
rwandan
ndiaye
sent
targett
younger
individuals
monograph
adults
secondary
some
dongo
karakire
here
committee
lancet
enrollment
malnutrition
unrestricted
ver
royal
raised
financial
den
393
kiggundu
non
aquine
given
addi
zion
moni
aged
reassuring
unwell
agranulocytosis
society
ipants
antiretroviral
droartemisinin
benefits
bridget
enzymes
focus
tolerability
article
paenia
ability
partic
blantyre
beckman
between
aspect
infectious
ous
symptom
residential
832
likely
parts
peer
corporation
prasanna
burkina
clin
424
detected
jurua
artem
epilepsy
acute
philip
anaemia
pathologists
dose
com
thought
chemistries
trial
france
giostra
kekitiinwa
fining
patrick
poration
vention
maxwell
td
makerere
des
creative
www
healthy
985
controlled
older
award
thrombocytopaenia
diseases
why
product
1department
households
children
saharan
evalu
day
rh
ature
240
stata
macarthur
william
115
lower
musoke
diarrhoea
specific
follows
scientist
degen
214
agencies
identi
illness
interests
geneva
using
single
american
since
3department
joaniter
reactions
1996
738
switzerland
infect
ing
occurred
ethics
involved
pj
other
ruth
1196
parents
licenses
term
363
clinicians
artesu
bn
except
allocation
university
prosenthal
gamble
another
rr
wilairatana
1474
target
makanga
125
temper
lost
sity
2008
entered
properties
mutabingwa
ticularly
clinically
initiation
nj
rwanda
written
seur
limited
manuscript
ther
plasmodium
completed
kwitonda
within
meya1
aventis
7ht
mh
actively
abdominal
guide
stratified
declare
pharmacovigilance
4epidemiological
hepatosplenomegaly
2004
swit
musinguzi
spontane
reports
generate
infocom
choice
graded
repeatedly
well
357
recent
dorsey
institutes
potential
newer
bakshi
297
olliaro
none
toovey
followed
asked
occurring
acts
mwebaze
scales
uk
m'bang'ombe
barnes
neutrophil
subjective
galinski
abnormalities
management
weakness
complicated
world
cohort
gasasira
hospital
ce
decrease
emergency
guidelines
syst
risks
joy
ruel
ers
jf
looareesuwan
118
358
achan
ngamije
talisuna4
optimal
tc
ugandan
used
figure
934
fulminant
nor
when
ratory
background
cant
cardiac
rela
exists
tice
pubmed
felix
copyright
possibly
http
differed
1999
rouamba
cerns
may
archived
bongole
348
chizani
emergence
terms
nurses
exclusion
wors
census
950
confirms
kalyango
caregivers
dura
examination
holds
further
sg
preferable
kam
november
int
number
ea
developing
randomly
isrctn37517549
541
untoward
organization
lumefantrine
institute
comparative
mpimbaza
managed
312
reg
now
237
mueller
population
dorsey2
kindly
100
286
oluga
how
jective
event
stern
their
pated
hoffman
nurse
605
administration
included
interpretation
tugaineyo
possi
yeka
296
retreated
tanzanian
trimethoprim
445
ciated
liver
required
rw
tablet
also
nevill
compliance
aq
markham
distribution
related
asso
cancer
015
but
small
therapeutic
advocated
over
found
briefly
sgs
eligibility
association
agreement
prevent
documented
kerr
ucsf
tamara
statistical
grading
abscess
1111
convulsion
harvard
citation
repeated
receive
convul
fund
cj
include
training
papers
evidence
low
nearly
his
jc
nzarubara1
mwesigwa
369
2875
participant's
through
while
maiteki
paul
hadengue
nificantly
sir
based
1200
ml
banek
developed
screening
comparisons
1108
purposes
parish
assigned
irrespective
generalized
favourable
charlebois
school
finally
mm3
alteri
safer
pain
made
page
tions
read
chemo
once
hospitalization
589
sam
transplantation
completion
persisting
febrile
such
greater
rexia
rebsamen
artekin
coinciding
persistent
826
jn
current
cber
pala
june
present
dokomajilar
minimal
intervention
offic
assessed
analysed
rockville
ria
wabwire
adjusting
jagannathan
elevated
time
d'alessandro
ment
292
guardians
rwakimari
version
uncom
5department
either
common
detect
health
routinely
human
review
twice
evaluating
lshtm
ule
values
arthur
hepatotoxicity
general
pa
nine
dren
watkins
five
cp
dexterity
regimens
concerns
international
artesunate
rs
has
2007
assessments
isuna
list
out
nzarubara
al
labo
medica
elevation
padilla
size
barigye
kokwaro
cd000016
simooya
days
publish
750
side
vy
prematurely
tablets
street
nankabirwa
clark2
passively
integra
medication
grant
cms
lines
doses
143
safety
short
jamieson
identifying
use
imprecision
until
chance
uncomplicated
majority
temperature
doren
601
343
epi
staedke
basel
therapy
extending
views
con
conference
261
charge
events
heller
require
ethical
visitors
essential
typical
sched
guardian
hermeling
safe
asp
appropriately
oue
subsequently
randomized
personnel
malawi
observed
established
malariajournal
began
willingness
reproduction
syndrome
not
surveillance
1120
years
attaran
loss
1475
halo
277
foundation
edu
effectiveness
pruritus
tory
onset
remain
vincentmyau
division
range
derivatives
hiv
informed
crite
cial
medium
133
particularly
severe
services
effect
tolerated
braus
remained
times
propensity
standard
workers
sey
community
before
notified
christopher
nwee
jr
abstract
team
statistically
acknowledgements
high
availability
above
laroche
falci
anthony
partici
cder
first
overall
sub
symptomatic
2003
dnm